ALXN News and Press, Alexion Pharmaceuticals Inc. From 02/17/21

Form 13F filings show fund managers' top arbitrage stocks. Top M&A stocks of the 31 funds I follow. Only two of the top 10 are cash deals. For further details see: Top Merger Stocks Held By Fund Managers, Mid-Q1 2021

Merger activity increased last week with five new deals announced. The acquisition of Glu Mobile by Electronic Arts. MKS Instruments and II-VI Incorporated bid for Coherent. For further details see: Merger Arbitrage Mondays - Bidding War For Coherent Continues

Shares of PhaseBio Pharmaceuticals (PHAS) are up more than 22% in early afternoon trading.There doesn't appear to be any news or other catalyst to explain the spike.Johnson & Johnson (JNJ) and AstraZeneca (AZN) own stakes in the microcap stock which has a market cap of just $133M.A Stifel...

Omeros' Biologics License Application (BLA) for orphan drug narsoplimab was accepted by FDA and was given priority review with FDA action date of July 17, 2021. This BLA is for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a rare...

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Alexion Pharmaceuticals (ALXN) Q4 results:Revenues: $1.59B (+15.2% Y/Y), beats by $80M.Key product sales: Soliris: $1.02B (+1%); Ultomiris: $313.5M (+84%); Strensiq: $185.9M (+11%); Andexxa: $39.6M; Kanuma: $29.2M (-14%).Net income: $535.8M (-...

Alexion Pharmaceuticals (ALXN): Q4 Non-GAAP EPS of $2.96 beats by $0.40; GAAP EPS of $2.42 beats by $0.20.Revenue of $1.59B (+15.2% Y/Y) beats by $80M.Shares +0.9% PM.Press Release For further details see: Alexion Pharmaceuticals EPS beats by $0.40, beats on revenue

4Q20 total revenues of $1,591.8 million, a 15% increase over 4Q19 4Q20 GAAP diluted EPS of $2.42; non-GAAP diluted EPS of $2.96 Announced agreement to be acquired by AstraZeneca; transaction expected to close in Q3 2021 Received EU approval for ULTOMIRIS ...

Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhibitor of the immunoproteasome with the potential to become a pipeline-in-a-pill for ...

Having overcome business challenges presented by the COVID-19 pandemic, the stock of Alexion Pharmaceuticals (ALXN) has been hitting new highs. We think it may be wise to bet on the stock now because this company has been receiving multiple regulatory approvals for its products. Headquart...